Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Repare Therapeutics's annualizedNet Income for the quarter that ended in Sep. 2025 was $13.03 Mil. Repare Therapeutics's average total tangible assets for the quarter that ended in Sep. 2025 was $128.62 Mil. Therefore, Repare Therapeutics's annualized Return-on-Tangible-Asset for the quarter that ended in Sep. 2025 was 10.13%.
The historical rank and industry rank for Repare Therapeutics's Return-on-Tangible-Asset or its related term are showing as below:
RPTX'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -102.57 Med: -30.36 Max: -7.93
Current: -46.04
During the past 8 years, Repare Therapeutics's highest Return-on-Tangible-Asset was -7.93%. The lowest was -102.57%. And the median was -30.36%.
RPTX's Return-on-Tangible-Asset is not ranked
in the Biotechnology industry.
Industry Median: -35.66
vs RPTX: -46.04
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Repare Therapeutics Return-on-Tangible-Asset Related Terms
Repare Therapeutics Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Repare Therapeutics's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RPTX vs MGNX, THAR, ANIX: Return-on-Tangible-Asset Comparison
For the Biotechnology subindustry, Repare Therapeutics's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Repare Therapeutics Return-on-Tangible-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Repare Therapeutics's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Repare Therapeutics's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Sep. 2025) net income data.
What does a Return-on-Tangible-Asset of 10.13% mean?
Repare Therapeutics (RPTX) has a Return-on-Tangible-Asset of 10.13% as of Sep. 2025. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Repare Therapeutics and its competitors.
Is Repare Therapeutics' Return-on-Tangible-Asset too high?
Repare Therapeutics' current Return-on-Tangible-Asset is 10.13%. Overall, Repare Therapeutics has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Repare Therapeutics' Return-on-Tangible-Asset compare to MGNX and THAR?
Repare Therapeutics' Return-on-Tangible-Asset of 10.13% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Biotechnology company?
A good Return-on-Tangible-Asset depends on the Biotechnology industry context. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Repare Therapeutics and its competitors. Repare Therapeutics's current Return-on-Tangible-Asset is 10.13%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Repare Therapeutics stock overvalued right now?
Repare Therapeutics (RPTX) has a current Return-on-Tangible-Asset of 10.13%. The stock's GF Value™ is $0.94, compared to a current price of $2.65 — trading 181.9% above its estimated fair value. The current Return-on-Tangible-Asset is 10.13%. Repare Therapeutics' overall GF Score™ is 20/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Repare Therapeutics (RPTX), the current Return-on-Tangible-Asset is 10.13% as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Repare Therapeutics (RPTX) Overvalued in 2026?
Based on GuruFocus' analysis, Repare Therapeutics stock appears to be overvalued.
The current stock price of $2.65 is trading 181.9% above its estimated GF Value™ of $0.94.
Key valuation signals for RPTX:
Return-on-Tangible-Asset: 10.13%
GF Value™: $0.94 vs. price of $2.65 (181.9% above fair value)
No single metric tells the full story. See the RPTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Repare Therapeutics Inc is a precision medicine oncology company focused on the development of synthetic lethality-based therapies for patients with cancer. The Company's focus is the research, development and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations.
20GF Score
Get the complete analysis for RPTX
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RPTX has been successfully added to your 
